🔬 Latest pharma industry updates 👇

🤝 Ipsen will buy Kartos Therapeutics, Inc. for up to $1.75B and Memo Therapeutics AG for over €700M to strengthen its rare disease pipeline.

💰 Abivax raised $920M in the U.S. after reassuring obefazimod data, strengthening its balance sheet before a planned FDA filing in ulcerative colitis.

💵 BridgeBio raised $1B in preferred equity to support Attruby growth and prepare 3 potential blockbuster U.S. launches.

🤝 Zymeworks Inc. will acquire Theravance Biopharma US, LLC for about $929M, adding COPD, inflammation, and immunology assets.

🚨 The Bundibugyo Ebola outbreak in Congo reached 1,115 cases and 304 deaths, with distrust, attacks on health workers, burned isolation tents, and misinformation severely hampering the response.

💉 Moderna shares jumped after FDA advisers unanimously backed its mRNA flu vaccine for adults 50+, with a final decision expected by August 5.

🎯 EU approved Enhertu as the 1st HER2-targeted therapy usable across unresectable or metastatic HER2-positive solid tumors, regardless of the cancer’s organ of origin.

🟢 FDA approved Viridian Therapeutics, Inc.’s Lumvoa for thyroid eye disease, setting up competition with Amgen’s Tepezza in a market analysts believe could be worth billions.

🕵️ U.S. lawmakers opened national security investigations into Merck, AbbVie, Lilly, Pfizer and BMS over clinical trials in China, including sites in Xinjiang and military hospitals.

🫁 Roche’s divarasib beat Lumakras and Krazati in Phase 3 KRAS G12C lung cancer, improving survival and progression-free survival with no new major safety concerns.

🤖 Anthropic launched Claude Science for researchers and pharma labs, offering tools to analyze biological datasets, review literature, generate hypotheses and visualize protein structures.

🧠 AlzeCure Pharma licensed its Alzheimer’s candidate ACD856 and NeuroRestore platform to QuantumCell in a deal worth over $2.2B.

💰 Celea raised $180M to launch Phase 3 testing of deupirfenidone in idiopathic pulmonary fibrosis, validating PureTech Health’s hub-and-spoke model for late-stage development.

🤝 AstraZeneca partnered with China’s CSPC Pharmaceutical Group in a siRNA deal worth up to $1.77B, targeting kidney diseases with extrahepatic delivery technology.

🤖 Takeda partnered with Insilico Medicine in an AI drug discovery deal worth up to $600M.

🧪 A clinical trial has begun in DRC testing MBP134 and remdesivir against Bundibugyo Ebola, while World Health Organization authorized the 1st emergency molecular diagnostic test for the strain.

🏛️ Richard Pazdur may return to the FDA in a senior role, a move seen as potentially stabilizing for an agency facing leadership turmoil.

🧬 Roche launched Axelios, a next-generation sequencer using reusable nanopore chips and near-real-time data, directly challenging Illumina with a lower U.S. price.